Follicular Lymphoma malady

Rare diseases, Cancer diseases, Blood diseases, Immune diseases categories

Aliases & Classifications for Follicular Lymphoma

About this section
30LifeMap Discovery®, 8Disease Ontology, 42NIH Rare Diseases, 48Orphanet, 61UMLS, 44Novoseek, 34MESH via Orphanet, 26ICD10 via Orphanet, 62UMLS via Orphanet, 25ICD10
See all sources

Aliases & Descriptions for Follicular Lymphoma:

Name: Follicular Lymphoma 30 8 42 48
Lymphoma, Follicular 42 61
Lymphoma Follicular 44


Characteristics (Orphanet epidemiological data):

follicular lymphoma:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult

External Ids:

Disease Ontology8 DOID:0050873
Orphanet48 545
MESH via Orphanet34 D008224
ICD10 via Orphanet26 C82
UMLS via Orphanet62 C0024301
ICD1025 C82

Summaries for Follicular Lymphoma

About this section
Disease Ontology:8 A non-hodgkin lymphoma that is characterized as an indolent non-hodgkin's lymphoma and has material basis in follicle center b-cells (centrocytes and centroblasts).

MalaCards based summary: Follicular Lymphoma, also known as lymphoma, follicular, is related to b-cell lymphomas and mantle cell lymphoma, and has symptoms including hyperhidrosis, weight loss and abnormality of temperature regulation. An important gene associated with Follicular Lymphoma is BCL2 (B-cell CLL/lymphoma 2), and among its related pathways are B Cell Receptor Signaling Pathway and Immune response Fc epsilon RI pathway. The drug ibritumomab tiuxetan has been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and t cells, and related mouse phenotype immune system.

Wikipedia:64 Follicular lymphoma is the most common of the indolent non-Hodgkin\'s lymphomas, and the... more...

Related Diseases for Follicular Lymphoma

About this section

Diseases related to Follicular Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 114)
idRelated DiseaseScoreTop Affiliating Genes
1b-cell lymphomas31.5BCL2, BCL6, C6orf25, IGHM, IGH
2mantle cell lymphoma31.2BCL2, BCL6
3hodgkin lymphoma31.1MSC
4malt lymphoma31.0IGH, IGHM, BCL6, BCL2
5chronic lymphocytic leukemia31.0IGH, IGHM, BCL6, BCL2, CD70
6burkitt lymphoma30.8BCL2, BCL6
7central nervous system lymphoma30.7BCL6
8diffuse large b-cell lymphoma10.8
11hematopoietic stem cell transplantation10.5
13gastric lymphoma10.4IGH, BCL6
14lymphosarcoma10.4IGH, BCL6, BCL2
15central nervous system lymphoma, primary10.4IGHM, BCL6
17paraneoplastic pemphigus10.4
18squamous cell carcinoma, head and neck10.4BCL2, IGHM, IGH
19reticulosarcoma10.4BCL2, BCL6, IGH
20waldenstrom macroglobulinemia10.3IGHM, IGH
21chromosomal triplication10.3BCL6, IGHM, IGH
22lymphoma, follicular, somatic10.3
23progressive multifocal leukoencephalopathy10.3
24lymphoblastic lymphoma10.3
25dendritic cell sarcoma10.3
27lymphoblastic leukemia10.3
28histiocytic sarcoma10.3
29leukemia, acute lymphoblastic10.2BCL2, BCL6, IGH
30plasmacytoma10.2BCL6, IGH
31myeloma10.2BCL2, BCL6, TNFRSF17, IGHM, IGH
32lymphomatoid granulomatosis10.2
33peripheral t-cell lymphoma10.2
34protein-losing enteropathy10.2
35follicular mucinosis10.2
36composite lymphoma10.2
40lymphoma, small cleaved-cell, follicular10.2
41plasmablastic lymphoma10.2
42primary effusion lymphoma10.2
43progressive transformation of germinal centers10.2
45transient acantholytic dermatosis10.2
46nodal marginal zone b-cell lymphoma10.2
47narcolepsy10.1HLA-DRB1, IGHM
48hiv-110.1BCL6, TNFRSF17, IGHM
49colorectal cancer10.0
50kaposi sarcoma10.0

Graphical network of the top 20 diseases related to Follicular Lymphoma:

Diseases related to follicular lymphoma

Symptoms for Follicular Lymphoma

About this section


 48 (show all 14)
  • hyperhidrosis/increased sweating
  • lymphadenopathy/polyadenopathies
  • hematologic/blood/lymphatic cancer
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • fever/chilling
  • splenomegaly
  • mediastinal/hilar adenopathies
  • asthenia/fatigue/weakness
  • anomalies of skin, subcutaneous tissue and mucosae
  • structural anomaly of the peritoneum
  • abnormal pleura/hydrothorax/pleuresia/pleural effusion/chylothorax
  • lymphedema
  • meningitis/meningeal syndrome
  • bone marrow/medullar infiltration

HPO human phenotypes related to Follicular Lymphoma:

(show all 10)
id Description Frequency HPO Source Accession
1 hyperhidrosis hallmark (90%) HP:0000975
2 weight loss hallmark (90%) HP:0001824
3 abnormality of temperature regulation hallmark (90%) HP:0004370
4 hematological neoplasm hallmark (90%) HP:0004377
5 splenomegaly typical (50%) HP:0001744
6 mediastinal lymphadenopathy typical (50%) HP:0100721
7 lymphedema occasional (7.5%) HP:0001004
8 meningitis occasional (7.5%) HP:0001287
9 abnormality of the pleura occasional (7.5%) HP:0002103
10 abnormality of the peritoneum occasional (7.5%) HP:0002585

Drugs & Therapeutics for Follicular Lymphoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Intron A13 38 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
FDA Label: Intron A
Malady that Drug Treats: non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:13 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years of; age or older with hairy cell leukemia.; Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in; patients 18 years of age or older with malignant melanoma who are free of disease but; at high risk for systemic recurrence, within 56 days of surgery.; Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically; aggressive (see Clinical Pharmacology) follicular Non-Hodgkin s Lymphoma in; conjunction with anthracycline-containing combination chemotherapy in patients 18; years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumor; burden follicular Non-Hodgkin s Lymphoma has not been demonstrated.; Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected; patients 18 years of age or older with condylomata acuminata involving external; surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).; The use of this product in adolescents has not been studied.; AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected; patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood; of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune; system as indicated by total CD4 count.; Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in; patients 18 years of age or older with compensated liver disease who have a history of; blood or blood-product exposure and/or are HCV antibody positive. Studies in these; patients demonstrated that INTRON A therapy can produce clinically meaningful effects; on this disease, manifested by normalization of serum alanine aminotransferase (ALT); and reduction in liver necrosis and degeneration.; A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.; Patients should be tested for the presence of antibody to HCV. Patients with other; causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior; to initiation of INTRON A therapy, the physician should establish that the patient has; compensated liver disease. The following patient entrance criteria for compensated liver; disease were used in the clinical studies and should be considered before INTRON A; treatment of patients with chronic hepatitis C:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; clinical signs of decompensation; Bilirubin Less than or equal to 2 mg/dL; Albumin Stable and within normal limits; Prothrombin Time Less than 3 seconds prolonged; WBC Greater than or equal to 3000/mm3; Platelets Greater than or equal to 70,000/mm3; Serum creatinine should be normal or near normal.; Prior to initiation of INTRON A therapy, CBC and platelet counts should be; evaluated in order to establish baselines for monitoring potential toxicity. These tests; should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and; monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals; to assess response to treatment (see DOSAGE AND ADMINISTRATION).; Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating; hormone (TSH) levels can be maintained in the normal range by medication.; TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH; testing should be repeated at 3 and 6 months (see PRECAUTIONS, Laboratory; Tests).; INTRON A in combination with REBETOL® is indicated for the treatment of; chronic hepatitis C in patients 3 years of age and older with compensated liver disease; previously untreated with alpha interferon therapy and in patients 18 years of age and; older who have relapsed following alpha interferon therapy. See REBETOL prescribing; information for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in; patients 1 year of age or older with compensated liver disease. Patients who have been; serum HBsAg positive for at least 6 months and have evidence of HBV replication; (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies; in these patients demonstrated that INTRON A therapy can produce virologic remission; of this disease (loss of serum HBeAg) and normalization of serum aminotransferases.; INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.; Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be; performed to establish the presence of chronic hepatitis and the extent of liver damage.; The physician should establish that the patient has compensated liver disease. The; following patient entrance criteria for compensated liver disease were used in the; clinical studies and should be considered before INTRON A treatment of patients with; chronic hepatitis B:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; signs of clinical decompensation; Bilirubin Normal; Albumin Stable and within normal limits; Prothrombin Time Adults less than 3 seconds prolonged; Pediatrics less than or equal to 2 seconds prolonged; WBC Greater than or equal to 4000/mm3; Platelets Adults greater than or equal to 100,000/mm3; Pediatrics greater than or equal to 150,000/mm3; Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic; hepatitis C should not be treated with INTRON A. CBC and platelet counts should be; evaluated prior to initiation of INTRON A therapy in order to establish baselines for; monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,; 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,; should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and; ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,; since patients may become virologic responders during the 6-month period; following the end of treatment. In clinical studies in adults, 39% (15/38) of responding; patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Of; responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.; A transient increase in ALT greater than or equal to 2 times baseline value (flare); can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults; and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and; was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in; nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and; pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal; to 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during; therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical; symptomatology and liver function tests including ALT, prothrombin time, alkaline; phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week; intervals (see WARNINGS).
DrugBank Targets:11 1. Interferon alpha/beta receptor 2; 2. Interferon alpha/beta receptor 1
Mechanism of Action:13 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
Zevalin13 38 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
FDA Label: Zevalin
Malady that Drug Treats: Non-Hodgkin's lymphoma
Indications and Usage:13 Zevalin is a CD20-directed radiotherapeutic antibody administered as part of; the Zevalin therapeutic regimen indicated for the treatment of patients with:; relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's; lymphoma (NHL) (1.1).; previously untreated follicular NHL who achieve a partial or complete; response to first-line chemotherapy (1.2). ;
DrugBank Targets:11 1. B-lymphocyte antigen CD20; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD20 antigen --> Y-90
Action: beta emission causes damage
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,; Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to; 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin s; lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.; The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90; induces cellular damage by the formation of free radicals in the target and neighboring cells.; Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and; white pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the; large and small intestines.

Drug clinical trials:

Search ClinicalTrials for Follicular Lymphoma

Search NIH Clinical Center for Follicular Lymphoma

Inferred drug relations via UMLS61/NDF-RT40:

Cell-based therapeutics:

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Follicular Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Follicular Lymphoma

About this section

Anatomical Context for Follicular Lymphoma

About this section

MalaCards organs/tissues related to Follicular Lymphoma:

B cells, Bone, T cells, Bone marrow, Lymph node, Skin, Colon, Breast, Monocytes, Testis, B lymphoblasts, Small intestine, Thyroid, Liver, Lung, Salivary gland, Nk cells, Endothelial

Animal Models for Follicular Lymphoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Follicular Lymphoma:

idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053879.0CD70, GCSAM, BCL2, BCL6, TNFRSF17, TNFRSF14

Publications for Follicular Lymphoma

About this section

Articles related to Follicular Lymphoma:

(show top 50)    (show all 818)
Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma. (25804839)
Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group. (23573825)
Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-I_B dependent human transformed follicular lymphoma cell line. (24386925)
Genetics of Follicular Lymphoma Transformation. (24388756)
X chromosome-wide association study of follicular lymphoma. (23795672)
Soluble interleukin-2 receptor level predicts survival in patients with follicular lymphoma treated with CHOP chemotherapy in the rituximab era. (24180329)
Synchronous adenocarcinoma and follicular lymphoma of the stomach. (23583995)
Peripheral blood involvement in patients with follicular lymphoma: a rare disease manifestation associated with poor prognosis. (24274024)
Coding variants at hexa-allelic amino acid 13 of HLA-DRB1 explain independent SNP associations with follicular lymphoma risk. (23791106)
Rituximab maintenance or retreatment after autologous transplantation for relapsed follicular lymphoma? (24062390)
The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. (23771004)
Chemotherapy versus autologous stem-cell transplantation for the treatment of transformed follicular lymphoma in the rituximab era. (23918946)
Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma. (22674621)
Imaging follicular lymphoma using positron emission tomography with [(18)F]fluorodeoxyglucose: to what purpose? (23109690)
Is autologous stem cell transplantation for transformed follicular lymphoma still justifiable? (22239667)
Long-term outcome after autologous or allogeneic stem cell transplantation in patients with recurrent follicular lymphoma. (22327132)
Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients? (22650448)
Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. (21811782)
Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? (23233615)
In situ follicular lymphoma with progressive transformation of the germinal centers confirmed by laser capture microdissection, IGH gene rearrangement analysis, and fluorescence in situ hybridization for t(14;18). (21733560)
Precision of histological bone marrow staging in follicular lymphoma and diffuse large B-cell lymphoma. (23217561)
Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. (22126847)
High frequency of t(14;18) in Hodgkin's lymphoma associated with follicular lymphoma. (22827759)
High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. (22258971)
Prognostic factors in follicular lymphoma in the rituximab era: how to identify a high-risk patient? (21804618)
Preferences of patients and physicians concerning treatment options for relapsed follicular lymphoma: a discrete choice experiment. (20935681)
BIOMED-2 PCR assays for IGK gene rearrangements are essential for B-cell clonality analysis in follicular lymphoma. (21790530)
An unusual presentation of follicular lymphoma. (20952121)
Biology and treatment of follicular lymphoma. (21083019)
Value of loss of CD10 expression in pathologic diagnosis of follicular lymphoma]. (20079015)
PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma. (17855629)
Transient acantholytic dermatosis associated with B symptoms of follicular lymphoma. (17868396)
Proteome- and microarray-based expression analysis of lymphoma cell lines identifies a p53-centered cluster of differentially expressed proteins in mantle cell and follicular lymphoma. (17990259)
Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. (17197448)
Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. (16492913)
Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. (15377470)
Detection of BCL2-IGH rearrangement on paraffin-embedded tissue sections obtained from a small submucosal tumor of the rectum in a patient with recurrent follicular lymphoma. (15300917)
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. (14767488)
Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. (12733111)
In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. (11964306)
Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. (12036852)
Variable heavy-chain gene analysis of follicular lymphomas: subclone selection rather than clonal evolution over time. (11418487)
Association of a duodenal follicular lymphoma and hereditary nonpolyposis colorectal cancer. (10824932)
Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma. (9209654)
Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation. (8622046)
A human follicular lymphoma B cell line hypermutates its functional immunoglobulin genes in vitro. (8566010)
MYC rearrangements in histologically progressed follicular lymphomas. (1638027)
CD30 expression in follicular lymphoma. (1849500)
Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. (3285208)
Radioimmunotherapy in follicular lymphoma: some like it hota8 (21334979)

Variations for Follicular Lymphoma

About this section

Expression for genes affiliated with Follicular Lymphoma

About this section
Search GEO for disease gene expression data for Follicular Lymphoma.

Pathways for genes affiliated with Follicular Lymphoma

About this section

Pathways related to Follicular Lymphoma according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.0BCL2, BCL6, IGHM
Show member pathways
Immune response BCR pathway59
Fc-epsilon receptor I signaling in mast cells36
Show member pathways
Immune response T cell receptor signaling pathway59
Immune response CD28 signaling59
Immune response ICOS pathway in T helper cell59
Show member pathways

Compounds for genes affiliated with Follicular Lymphoma

About this section

GO Terms for genes affiliated with Follicular Lymphoma

About this section

Cellular components related to Follicular Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1plasma membraneGO:00058868.4CD70, GCSAM, P2RY8, C6orf25, TNFRSF17, TNFRSF14

Biological processes related to Follicular Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of B cell proliferationGO:003089010.2BCL2, BCL6
2negative regulation of G1/S transition of mitotic cell cycleGO:0200013410.2BCL2, ZC3H12D
3negative regulation of cell growthGO:003030810.1ZC3H12D, BCL2, BCL6
4defense response to Gram-negative bacteriumGO:005082910.0TNFRSF14, IGHM
5immune responseGO:00069559.8CD70, TNFRSF14, HLA-DRB1, IGKV1-5
6tumor necrosis factor-mediated signaling pathwayGO:00332099.7TNFRSF17, TNFRSF14

Molecular functions related to Follicular Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1tumor necrosis factor-activated receptor activityGO:000503110.0TNFRSF17, TNFRSF14

Sources for Follicular Lymphoma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet